Results of the interim analysis of KEYNOTE-859 are in, and they confirm the overall survival benefit of first-line immunotherapy plus chemotherapy in advanced gastric cancer. Pembrolizumab plus a fluoropyrimidine- and platinum-containing doublet provided a statistically ...
[2]Huang D, Lu N, Fan Q, et al.HER-2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study. PLoS One. 2013;8(11):e80290. [3]Bang YJ, et al. Trastuzumab in combination with chemotherapy versus chemothera...
[2]Huang D, Lu N, Fan Q, et al. HER-2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study. PLoS One. 2013;8(11):e80290. [...
Abstract CT037: Canakinumab in combination with first-line (1L) pembrolizumab plus chemotherapy for advanced non-small cell lung cancer (aNSCLC): Results f... plus chemotherapy.\nMethods: CANOPY-1 is a randomized, double-blind phase 3 study investigating the addition of canakinumab or placebo (...
In the U.S., KEYTRUDA is also approved for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma, based on results from KEYNOTE-85...
英国剑桥大学医院Elizabeth Smyth教授受邀进行点评。在晚期GC/GEJC一线治疗中,CheckMate-649、RATIONALE-305和KEYNOTE-859等研究已证实,免疫+化疗可带来OS获益,PD-L1阳性患者获益更大。 而对于可手术GC/GEJC,围手术期治疗的目标有3个: 1...
In KEYNOTE-859, when KEYTRUDA was administered in combination with fluoropyrimidine- and platinum-containing chemotherapy, serious adverse reactions occurred in 45% of 785 patients. Serious adverse reactions in >2% of patients included pneumonia (4.1%), diarrhea (3.9%), hemorrhage (3.9%), ...
But I've been getting into timed animations and the results are quite amazing. Do lots of other people do this? https://youtu.be/Gm8TTyUhJFg Posted on Oct 26, 2023 7:58 PM Me too Reply Similar questions animation in keynote Hello, I am wondering how to set up an endless loop...
Results will be presented at an upcoming medical meeting and shared with regulatory authorities. “This is a significant milestone, as it is the first time an immunotherapy-based regimen has demonstrated a statistically significant overall s...
Results At data cutoff, 7 of 174 patients (4.0%) in KEYNOTE-059, 27 of 514 patients (5.3%) in KEYNOTE-061, and 50 of 682 patients (7.3%) in KEYNOTE-062 had MSI-H tumors. Among those with MSI-H tumors, the median overall survival was not reached (NR) for pembrolizumab in KEY...